Atropine-Scopolamine Formulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current countermeasures for organophosphate nerve agent exposure suffer from shelf-life instability and inadequate efficacy, particularly in addressing nicotinic-based effects such as seizures and behavioral deficits, with atropine requiring high doses that can be toxic and having limited ability to bypass the blood-brain barrier.
Innovation Solution
A stable formulation comprising atropine and scopolamine, combined with ethanol, which provides optimal muscarinic receptor blockade and anticholinergic activity, offering improved shelf-stability and bioavailability, allowing for rapid response to OPNA exposure without the need for specialized manufacturing or sterility assurance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If atropine is used alone to treat organophosphate nerve agent exposure, then muscarinic symptoms are addressed, but nicotinic-based effects such as seizures and behavioral deficits are not adequately treated, and high doses required are toxic
Solution Approach 1:
The patent combines atropine and scopolamine in a single formulation to achieve both peripheral and central anticholinergic effects. Atropine addresses muscarinic symptoms while scopolamine penetrates the blood-brain barrier to treat central nervous system effects including seizures and behavioral deficits, eliminating the need for high toxic doses of atropine alone
Solution Approach 2:
The combined atropine-scopolamine formulation serves multiple functions simultaneously: it blocks peripheral muscarinic receptors (atropine), penetrates the blood-brain barrier to block central muscarinic receptors (scopolamine), and provides both preventive and therapeutic effects against organophosphate nerve agent exposure, making it a universal countermeasure
2Reliability
If current countermeasure formulations are used, then treatment function is provided, but shelf-life instability occurs and usefulness is reduced
Solution Approach 1:
The patent optimizes formulation parameters including pH (adjusted to 3.0-4.0 using citrate buffer), ethanol concentration (10-40% v/v), and component ratios to achieve enhanced chemical stability. These parameter changes prevent degradation of atropine and scopolamine during storage, extending shelf-life while maintaining therapeutic effectiveness
Solution Approach 2:
The invention creates a composite formulation system combining atropine, scopolamine, ethanol, and citrate buffer in specific proportions. This composite material provides synergistic stability, where the ethanol-citrate system prevents hydrolysis and oxidation of the active ingredients, ensuring long-term shelf-life stability
3Reliability
If specialized manufacturing and sterility assurance are required, then product quality is ensured, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent employs a disposable autoinjector device with pre-filled sterile cartridges containing the atropine-scopolamine formulation. The entire device is designed for single use, eliminating complex sterilization and manufacturing processes while ensuring product quality through factory-sealed sterile packaging
Data Source
AI summary
This disclosure relates to stable formulations of atropine and scopolamine for use as a medical countermeasure to combat organophosphate nerve agent threats. The formulations exploit complementary pharmacological profiles for optimal receptor blockade and anticholinergic activity within the peripheral and central nervous system. The formulations are suitable for intramuscular injection, and have stability that exceeds two years in stressed conditions.